サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
市場調査レポート
商品コード
1494520

北米のマイクロバイオーム治療薬：2030年までの予測- 地域別分析- タイプ別、用途別、エンドユーザー別

North America Microbiome Therapeutics Market Forecast to 2030 - Regional Analysis - by Type, Application, and End User

出版日
ページ情報
英文 68 Pages
納期
即納可能 即納可能とは
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=143.57円
北米のマイクロバイオーム治療薬：2030年までの予測- 地域別分析- タイプ別、用途別、エンドユーザー別
出版日: 2024年04月05日
発行: The Insight Partners
ページ情報: 英文 68 Pages
納期: 即納可能 即納可能とは
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

北米のマイクロバイオーム治療薬市場は、2022年に1億6,164万米ドルと評価され、2030年には3億4,299万米ドルに達すると予測され、2022年から2030年までのCAGRは9.9%を記録すると予測されています。

マイクロバイオーム探索パイプライン改善のための資金流入が北米のマイクロバイオーム治療薬市場を牽引

調査により、マイクロバイオームのバランスの乱れや崩壊が、炎症性腸疾患や肥満、精神疾患などさまざまな疾患の原因となることが示されています。健康全般におけるマイクロバイオームの役割が認識されたことで、マイクロバイオームを標的とし調整する治療薬の開発に大きな関心が集まっています。さらに、技術や研究ツールの進歩により、マイクロバイオームの研究や操作が容易になった。次世代シーケンサーとメタゲノム解析により、微生物群集とその機能がより深く理解できるようになった。知識が深まったことで、標的療法開発の新たな可能性が開かれました。米国食品医薬品局（FDA）などの規制当局も、マイクロバイオーム治療薬の開発を支援する姿勢を示しています。FDAはFMTのガイドラインを制定し、安全性と有効性を確保する規制経路を通じてこの分野を前進させることに関心を示しています。これらすべての要因が相まって、マイクロバイオーム治療薬の分野で活動する企業にとって有利な投資環境が整っています。

強力な臨床エビデンスが得られるようになり、投資家はマイクロバイオームモジュレーター企業に注目し始めています。資金調達が活発化することで、企業は高い開発・生産コストに伴う課題を克服するために必要なリソースを得ることができ、最終的にこの分野を前進させる原動力となっています。

北米のマイクロバイオーム治療薬市場の概要

健康維持と疾病予防におけるヒトマイクロバイオームの重要性に対する理解が深まるにつれ、米国の研究者らはマイクロバイオームに基づく介入をさまざまな病態の治療に有望なアプローチとして模索するようになった。さらに、肥満や炎症性腸疾患などの慢性疾患の有病率の上昇が革新的な治療に対する需要を生み出し、マイクロバイオーム治療薬の開発に拍車をかけています。遺伝子配列決定やバイオインフォマティクスの技術的進歩により、マイクロバイオームの研究や改変が可能になり、個別化されたマイクロバイオームに基づく介入の開発が促進されています。個別化医療の動向は、オーダーメイドのマイクロバイオーム治療薬とよく合致しています。学術界、産業界、政府機関の連携も研究開発に拍車をかけ、科学的発見の商業製品への転換を加速させています。規制当局がマイクロバイオーム治療薬の可能性を認識し、その開発と承認のためのガイダンスを提供しているため、この分野に対する規制当局の支援と投資はさらに市場の成長に貢献しています。

北米のマイクロバイオーム治療薬市場の収益と2030年までの予測（金額）

北米のマイクロバイオーム治療薬市場のセグメンテーション

北米のマイクロバイオーム治療薬市場は、タイプ、用途、エンドユーザー、国に基づいてセグメント化されます。

タイプ別に見ると、北米のマイクロバイオーム治療薬市場は治療薬と手技に二分されます。2022年には、処置セグメントがより大きなシェアを占めています。治療薬セグメントはさらに、糞便微生物叢移植（FMT）、プレバイオティクス＆プロバイオティクス、その他に細分化されます。

用途別では、北米のマイクロバイオーム治療薬市場は、代謝障害・肥満、C. difficile感染症、炎症性腸疾患、その他に区分されます。2022年にはC.ディフィシル感染症分野が最大のシェアを占めました。

エンドユーザー別では、北米のマイクロバイオーム治療薬市場は病院・クリニック、外来手術センター、在宅医療、その他に分類されます。病院・診療所セグメントが2022年に最大シェアを占めました。

国別に見ると、北米のマイクロバイオーム治療薬市場は米国、カナダ、メキシコに区分されます。2022年の北米のマイクロバイオーム治療薬市場は米国が独占。

AOBiome Therapeutics Inc、Ferring Holdings SA、Finch Therapeutics Group Inc、Pendulum Therapeutics Inc、Seres Therapeutics Incなどは、北米のマイクロバイオーム治療薬市場で事業を展開する大手企業です。

目次

第1章 イントロダクション

第2章 エグゼクティブサマリー

  • 主要な洞察

第3章 調査手法

  • 調査範囲
  • 2次調査
  • 1次調査

第4章 北米のマイクロバイオーム治療薬市場情勢

  • 概観
  • 北米のPEST分析

第5章 北米のマイクロバイオーム治療薬市場- 主要産業力学

  • 北米のマイクロバイオーム治療薬市場- 主要産業力学
  • 主な市場促進要因
    • ヒトの健康維持における腸内細菌叢の可能性
    • マイクロバイオーム探索パイプラインを改善するための資金流入
  • 主な市場抑制要因
    • 開発・生産コストの高さ
  • 主な市場機会
    • ヒトマイクロバイオームの理解を深めるための研究開発の増加
  • 主な将来動向
    • ヒトマイクロバイオーム治療薬の技術的進歩
  • 促進要因と抑制要因の影響

第6章 マイクロバイオーム治療薬市場-北米市場分析

第7章 北米のマイクロバイオーム治療薬市場分析：タイプ別

  • 治療薬
  • 施術

第8章 北米のマイクロバイオーム治療薬市場分析：用途別

  • 代謝異常と肥満
  • C. difficile感染症（CDI）
  • 炎症性腸疾患
  • その他

第9章 北米のマイクロバイオーム治療薬市場分析：エンドユーザー別

  • 病院とクリニック
  • 外来手術センター
  • 在宅ケア
  • その他

第10章 北米のマイクロバイオーム治療薬市場：国別分析

  • 米国
  • カナダ
  • メキシコ

第11章 業界情勢

  • 北米のマイクロバイオーム治療薬市場の成長戦略

第12章 企業プロファイル

  • Ferring Holdings SA
  • Vedanta Biosciences Inc
  • Finch Therapeutics Group Inc
  • Pendulum Therapeutics Inc
  • Seres Therapeutics Inc
  • AOBiome Therapeutics Inc

第13章 付録

図表

List Of Tables

  • Table 1. North America Microbiome Therapeutics Market Segmentation
  • Table 2. North America Microbiome Therapeutics Market Revenue and Forecasts to 2030 (US$ Thousand) - Type
  • Table 3. North America Microbiome Therapeutics Market Revenue and Forecasts to 2030 (US$ Thousand) - Therapeutics
  • Table 4. North America Microbiome Therapeutics Market Revenue and Forecasts to 2030 (US$ Thousand) - Application
  • Table 5. North America Microbiome Therapeutics Market Revenue and Forecasts to 2030 (US$ Thousand) - End User
  • Table 6. North America Microbiome Therapeutics Market Revenue and Forecasts To 2030 (US$ Thousands) - By Country
  • Table 7. US: North America Microbiome Therapeutics Market Revenue and Forecasts To 2030 (US$ Thousands) - By Type
  • Table 8. US: North America Microbiome Therapeutics Market Revenue and Forecasts To 2030 (US$ Thousands) - By Therapeutics
  • Table 9. US: North America Microbiome Therapeutics Market Revenue and Forecasts To 2030 (US$ Thousands) - By Application
  • Table 10. US: North America Microbiome Therapeutics Market Revenue and Forecasts To 2030 (US$ Thousands) - By End User
  • Table 11. Canada: North America Microbiome Therapeutics Market Revenue and Forecasts To 2030 (US$ Thousands) - By Type
  • Table 12. Canada: North America Microbiome Therapeutics Market Revenue and Forecasts To 2030 (US$ Thousands) - By Therapeutics
  • Table 13. Canada: North America Microbiome Therapeutics Market Revenue and Forecasts To 2030 (US$ Thousands) - By Application
  • Table 14. Canada: North America Microbiome Therapeutics Market Revenue and Forecasts To 2030 (US$ Thousands) - By End User
  • Table 15. Mexico: North America Microbiome Therapeutics Market Revenue and Forecasts To 2030 (US$ Thousands) - By Type
  • Table 16. Mexico: North America Microbiome Therapeutics Market Revenue and Forecasts To 2030 (US$ Thousands) - By Therapeutics
  • Table 17. Mexico: North America Microbiome Therapeutics Market Revenue and Forecasts To 2030 (US$ Thousands) - By Application
  • Table 18. Mexico: North America Microbiome Therapeutics Market Revenue and Forecasts To 2030 (US$ Thousands) - By End User
  • Table 19. Recent Growth Strategies in North America Microbiome Therapeutics Market
  • Table 20. Glossary of Terms, North America Microbiome Therapeutics Market

List Of Figures

  • Figure 1. North America Microbiome Therapeutics Market Segmentation, By Country
  • Figure 2. North America PEST Analysis
  • Figure 3. Impact Analysis of Drivers and Restraints
  • Figure 4. North America Microbiome Therapeutics Market Revenue (US$ Thousand), 2022 - 2030
  • Figure 5. North America Microbiome Therapeutics Market Share (%) - Type, 2022 and 2030
  • Figure 6. Therapeutics Market Revenue and Forecasts to 2030 (US$ Thousand)
  • Figure 7. Procedure Market Revenue and Forecasts to 2030 (US$ Thousand)
  • Figure 8. North America Microbiome Therapeutics Market Share (%) - Application, 2022 and 2030
  • Figure 9. Metabolic Disorder and Obesity Market Revenue and Forecasts to 2030 (US$ Thousand)
  • Figure 10. C. Difficile Infection (CDI) Market Revenue and Forecasts to 2030 (US$ Thousand)
  • Figure 11. Inflammatory Bowel Disease Market Revenue and Forecasts to 2030 (US$ Thousand)
  • Figure 12. Others Market Revenue and Forecasts to 2030 (US$ Thousand)
  • Figure 13. North America Microbiome Therapeutics Market Share (%) - End User, 2022 and 2030
  • Figure 14. Hospitals and Clinics Market Revenue and Forecasts to 2030 (US$ Thousand)
  • Figure 15. Ambulatory Surgical Centers Market Revenue and Forecasts to 2030 (US$ Thousand)
  • Figure 16. Homecare Market Revenue and Forecasts to 2030 (US$ Thousand)
  • Figure 17. Others Market Revenue and Forecasts to 2030 (US$ Thousand)
  • Figure 18. North America Microbiome Therapeutics Market Breakdown by Key Countries - Revenue (2022) (US$ Thousand)
  • Figure 19. North America Microbiome Therapeutics Market Breakdown by Key Countries, 2022 and 2030 (%)
  • Figure 20. US: North America Microbiome Therapeutics Market Revenue and Forecasts To 2030 (US$ Thousands)
  • Figure 21. Canada: North America Microbiome Therapeutics Market Revenue and Forecasts To 2030 (US$ Thousands)
  • Figure 22. Mexico: North America Microbiome Therapeutics Market Revenue and Forecasts To 2030 (US$ Thousands)
目次
Product Code: BMIRE00029954

The North America microbiome therapeutics market was valued at US$ 161.64 million in 2022 and is expected to reach US$ 342.99 million by 2030; it is estimated to record a CAGR of 9.9% from 2022 to 2030.

Inflow of Funds to Ameliorate Microbiome Discovery Pipeline Drives North America Microbiome Therapeutics Market

Research has shown that imbalances or disruptions in the microbiome can contribute to various conditions, such as inflammatory bowel disease and obesity, as well as mental health disorders. The recognition of the microbiome's role in overall health has generated significant interest in developing therapeutics to target and modulate the microbiome. Additionally, advancements in technology and research tools have made it easier to study and manipulate the microbiome. Next-generation sequencing and metagenomic analysis have allowed for a deeper understanding of microbial communities and their functions. The increased knowledge has opened up new possibilities for developing targeted therapies. Regulatory agencies such as the US Food and Drug Administration (FDA) have also shown a willingness to support the development of microbiome therapeutics. The FDA has established guidelines for FMT and has expressed interest in advancing the field through regulatory pathways that ensure safety and efficacy. All these factors combined have created a favorable investment climate for companies working in the field of microbiome therapeutics.

As strong clinical evidence becomes available, investors are beginning to take notice of microbiome modulator firms. The heightened funding provides companies with necessary resources to overcome the challenges associated with the high cost of development and production, ultimately driving the field forward.

North America Microbiome Therapeutics Market Overview

The increasing understanding of the importance of the human microbiome in maintaining health and preventing diseases has led researchers in the US to explore microbiome-based interventions as a promising approach to treating various conditions. Additionally, the dominance of this country in the North America microbiome therapeutics market is mainly attributed to its well-developed research infrastructure that favors the development of innovative treatments Further, the rising prevalence of chronic diseases such as obesity and inflammatory bowel disease has created a demand for innovative treatments, spurring the development of microbiome therapeutics. Technological advancements in gene sequencing and bioinformatics enable the study and alteration of the microbiome, facilitating the development of personalized microbiome-based interventions. The trend toward personalized medicine aligns well with tailormade microbiome therapeutics. Collaborations between academia, industry, and government organizations are also fueling research and development efforts, accelerating the translation of scientific discoveries into commercial products. Regulatory support and investment in the field further contribute to market growth, as regulatory bodies recognize the potential of microbiome therapeutics and provide guidance for their development and approval.

North America Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Million)

North America Microbiome Therapeutics Market Segmentation

The North America microbiome therapeutics market is segmented based on type, application, end user, and country.

Based on type, the North America microbiome therapeutics market is bifurcated into therapeutics and procedure. The procedure segment held a larger share in 2022. The therapeutics segment is further subsegmented into fecal microbiota transplantation (FMT), prebiotics & probiotics, and others.

By application, the North America microbiome therapeutics market is segmented into metabolic disorder and obesity, C. difficile infection, inflammatory bowel disease, and others. The C. difficile infection segment held the largest share in 2022.

By end user, the North America microbiome therapeutics market is hospitals and clinics, ambulatory surgical centers, homecare, and others. The hospitals and clinics segment held the largest share in 2022.

Based on country, the North America microbiome therapeutics market is segmented into the US, Canada, and Mexico. The US dominated the North America microbiome therapeutics market in 2022.

AOBiome Therapeutics Inc, Ferring Holdings SA, Finch Therapeutics Group Inc, Pendulum Therapeutics Inc, and Seres Therapeutics Inc are some of the leading companies operating in the North America microbiome therapeutics market.

Table Of Contents

1. Introduction

  • 1.1 The Insight Partners Research Report Guidance
  • 1.2 Market Segmentation

2. Executive Summary

  • 2.1 Key Insights

3. Research Methodology

  • 3.1 Coverage
  • 3.2 Secondary Research
  • 3.3 Primary Research

4. North America Microbiome Therapeutics Market Landscape

  • 4.1 Overview
  • 4.2 North America PEST Analysis

5. North America Microbiome Therapeutics Market - Key Industry Dynamics

  • 5.1 North America Microbiome Therapeutics Market - Key Industry Dynamics
  • 5.2 Key Market Drivers
    • 5.2.1 Potential of Gut Microbiota in Maintaining Human Health
    • 5.2.2 Inflow of Funds to Ameliorate Microbiome Discovery Pipeline
  • 5.3 Key Market Restraints
    • 5.3.1 High Cost of Development and Production
  • 5.4 Key Market Opportunities
    • 5.4.1 Increasing R&D to Gain Better Understanding of Human Microbiome
  • 5.5 Key Future Trends
    • 5.5.1 Technological Advancement in Human Microbiome Therapeutics
  • 5.6 Impact of Drivers and Restraints:

6. Microbiome Therapeutics Market - North America Market Analysis

7. North America Microbiome Therapeutics Market Analysis - Type

  • 7.1 Therapeutics
    • 7.1.1 Overview
    • 7.1.2 Therapeutics Market, Revenue and Forecast to 2030 (US$ Thousand)
  • 7.2 Procedure
    • 7.2.1 Overview
    • 7.2.2 Procedure Market, Revenue and Forecast to 2030 (US$ Thousand)

8. North America Microbiome Therapeutics Market Analysis - Application

  • 8.1 Metabolic Disorder and Obesity
    • 8.1.1 Overview
    • 8.1.2 Metabolic Disorder and Obesity Market, Revenue and Forecast to 2030 (US$ Thousand)
  • 8.2 C. Difficile Infection (CDI)
    • 8.2.1 Overview
    • 8.2.2 C. Difficile Infection (CDI) Market, Revenue and Forecast to 2030 (US$ Thousand)
  • 8.3 Inflammatory Bowel Disease
    • 8.3.1 Overview
    • 8.3.2 Inflammatory Bowel Disease Market, Revenue and Forecast to 2030 (US$ Thousand)
  • 8.4 Others
    • 8.4.1 Overview
    • 8.4.2 Others Market, Revenue and Forecast to 2030 (US$ Thousand)

9. North America Microbiome Therapeutics Market Analysis - End User

  • 9.1 Hospitals and Clinics
    • 9.1.1 Overview
    • 9.1.2 Hospitals and Clinics Market, Revenue and Forecast to 2030 (US$ Thousand)
  • 9.2 Ambulatory Surgical Centers
    • 9.2.1 Overview
    • 9.2.2 Ambulatory Surgical Centers Market, Revenue and Forecast to 2030 (US$ Thousand)
  • 9.3 Homecare
    • 9.3.1 Overview
    • 9.3.2 Homecare Market, Revenue and Forecast to 2030 (US$ Thousand)
  • 9.4 Others
    • 9.4.1 Overview
    • 9.4.2 Others Market, Revenue and Forecast to 2030 (US$ Thousand)

10. North America Microbiome Therapeutics Market - Country Analysis

  • 10.1 North America Microbiome Therapeutics Market Revenue and Forecasts and Analysis - By Country
    • 10.1.1 North America Microbiome Therapeutics Market Revenue and Forecasts and Analysis - By Country
    • 10.1.2 US
      • 10.1.2.1 US: North America Microbiome Therapeutics Market Revenue and Forecasts to 2030 (US$ Thousands)
      • 10.1.2.2 US: North America Microbiome Therapeutics Market Breakdown by Type
        • 10.1.2.2.1 US North America Microbiome Therapeutics Market Breakdown by Therapeutics
      • 10.1.2.3 US: North America Microbiome Therapeutics Market Breakdown by Application
      • 10.1.2.4 US: North America Microbiome Therapeutics Market Breakdown by End User
    • 10.1.3 Canada
      • 10.1.3.1 Canada: North America Microbiome Therapeutics Market Revenue and Forecasts to 2030 (US$ Thousands)
      • 10.1.3.2 Canada: North America Microbiome Therapeutics Market Breakdown by Type
        • 10.1.3.2.1 Canada North America Microbiome Therapeutics Market Breakdown by Therapeutics
      • 10.1.3.3 Canada: North America Microbiome Therapeutics Market Breakdown by Application
      • 10.1.3.4 Canada: North America Microbiome Therapeutics Market Breakdown by End User
    • 10.1.4 Mexico
      • 10.1.4.1 Mexico: North America Microbiome Therapeutics Market Revenue and Forecasts to 2030 (US$ Thousands)
      • 10.1.4.2 Mexico: North America Microbiome Therapeutics Market Breakdown by Type
        • 10.1.4.2.1 Mexico: North America Microbiome Therapeutics Market Breakdown by Therapeutics
      • 10.1.4.3 Mexico: North America Microbiome Therapeutics Market Breakdown by Application
      • 10.1.4.4 Mexico: North America Microbiome Therapeutics Market Breakdown by End User

11. Industry Landscape

  • 11.1 Overview
  • 11.2 Growth Strategies in North America Microbiome Therapeutics Market

12. Company Profiles

  • 12.1 Ferring Holdings SA
    • 12.1.1 Key Facts
    • 12.1.2 Business Description
    • 12.1.3 Products and Services
    • 12.1.4 Financial Overview
    • 12.1.5 SWOT Analysis
    • 12.1.6 Key Developments
  • 12.2 Vedanta Biosciences Inc
    • 12.2.1 Key Facts
    • 12.2.2 Business Description
    • 12.2.3 Products and Services
    • 12.2.4 Financial Overview
    • 12.2.5 SWOT Analysis
    • 12.2.6 Key Developments
  • 12.3 Finch Therapeutics Group Inc
    • 12.3.1 Key Facts
    • 12.3.2 Business Description
    • 12.3.3 Products and Services
    • 12.3.4 Financial Overview
    • 12.3.5 SWOT Analysis
    • 12.3.6 Key Developments
  • 12.4 Pendulum Therapeutics Inc
    • 12.4.1 Key Facts
    • 12.4.2 Business Description
    • 12.4.3 Products and Services
    • 12.4.4 Financial Overview
    • 12.4.5 SWOT Analysis
    • 12.4.6 Key Developments
  • 12.5 Seres Therapeutics Inc
    • 12.5.1 Key Facts
    • 12.5.2 Business Description
    • 12.5.3 Products and Services
    • 12.5.4 Financial Overview
    • 12.5.5 SWOT Analysis
    • 12.5.6 Key Developments
  • 12.6 AOBiome Therapeutics Inc
    • 12.6.1 Key Facts
    • 12.6.2 Business Description
    • 12.6.3 Products and Services
    • 12.6.4 Financial Overview
    • 12.6.5 SWOT Analysis
    • 12.6.6 Key Developments

13. Appendix

  • 13.1 About The Insight Partners
  • 13.2 Glossary of Terms